Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)

Barinthus Biotherapeutics filings provide 5 years of Receivables readings, the most recent being $7.1 million for Q4 2024.

  • On a quarterly basis, Receivables rose 45.46% to $7.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $7.1 million, a 45.46% increase, with the full-year FY2024 number at $7.1 million, changed N/A from a year prior.
  • Receivables hit $7.1 million in Q4 2024 for Barinthus Biotherapeutics, up from $5.2 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $18.2 million in Q1 2022 to a low of $940000.0 in Q1 2023.
  • Median Receivables over the past 5 years was $5.1 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Receivables: crashed 94.83% in 2023 and later surged 452.77% in 2024.
  • Barinthus Biotherapeutics' Receivables stood at $3.2 million in 2020, then soared by 93.71% to $6.2 million in 2021, then soared by 60.68% to $10.0 million in 2022, then tumbled by 51.12% to $4.9 million in 2023, then soared by 45.46% to $7.1 million in 2024.
  • The last three reported values for Receivables were $7.1 million (Q4 2024), $5.2 million (Q1 2024), and $4.9 million (Q4 2023) per Business Quant data.